Abilify Asimtufii 720 mg (Aripiprazole SUSPENSION (EXTENDED-RELEASE)) 720 MG

Abilify Asimtufii 720 mg is an extended-release suspension of aripiprazole, used for managing certain mental health conditions. This intramuscular formulation provides long-lasting effects, offering a convenient treatment option.

Strength

720 MG

Manufacturer / TM Owner

OTSUKA PHARMACEUTICAL CO LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Abilify Asimtufii 720 mg is primarily used for the treatment of schizophrenia and bipolar disorder. This extended-release suspension is administered intramuscularly, providing a sustained release of aripiprazole. Patients often wonder, 'What is Abilify Asimtufii used for?' It is designed to help manage symptoms associated with these conditions, offering a long-lasting therapeutic effect.

Side Effects

Common effects of Abilify Asimtufii 720 mg may include drowsiness, dizziness, and mild nausea. Some users may experience restlessness or mild tremors. These effects can vary depending on individual responses to the medication.

Precautions & Warnings

Abilify Asimtufii 720 mg should be handled with care, ensuring proper storage and administration. It is important to follow the guidance of a healthcare professional regarding its use. Patients should be monitored for any unusual reactions or side effects.

Avoid Interactions

Abilify Asimtufii 720 mg may interact with certain medications, including those that affect the central nervous system. Alcohol and other depressants should be avoided, as they can enhance the sedative effects. Always consult a healthcare provider before combining with other treatments.

Frequently Asked Questions

Abilify Asimtufii 720 mg is used for managing symptoms of schizophrenia and bipolar disorder.

Abilify Asimtufii 720 mg is administered intramuscularly as an extended-release suspension.

Common side effects may include drowsiness, dizziness, and mild nausea.

It may interact with certain medications, so it is important to consult a healthcare provider before combining treatments.

Proper storage instructions should be followed as advised by the healthcare provider or product guidelines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.